Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Innova Biosciences and TGR BioSciences Announce Co-Marketing Agreement

Published: Thursday, January 16, 2014
Last Updated: Thursday, January 16, 2014
Bookmark and Share
Companies enter into an agreement to promote and co-market each other’s highly complementary technologies.

The agreement provides customers with a major step forward in simplifying the ELISA development process, while improving sensitivity and reducing costs.  

TGR has determined that combining Innova’s Lightning-Link conjugation kits for the horseradish peroxidase (HRP) labelling of antibodies with its CaptSure technology in the development of ELISA systems maximises assay sensitivity, whilst enabling the development of a wide range of ELISA assays rapidly and cost effectively. As part of the agreement Innova customers will be introduced to the CaptSure technology, with the assurance that it will work alongside the Lightning-Link reagents. Similarly, TGR customers will receive a recommendation for Lightning-Link, with the knowledge that it will be available for licensing to them, should they choose to use it alongside CaptSure products.

TGR’s CaptSure technology simplifies ELISA assays to one-step procedures, making them much faster and easier to carry out. Both assay antibodies are added to analyte at once, and after a single wash step the HRP substrate is added to develop the signal. Importantly, costs of manufacture are greatly reduced, since only a single assay plate is required (coated with CaptSure reagent) rather than a different plate for each target, and the system also requires much less assay antibodies.

Innova’s Lightning-Link conjugation system provides the ability to label antibodies with only 30 seconds hands-on time, whilst offering 100% yields and enhanced sensitivity over traditional labelling techniques and over other conjugation systems on the market.

Dr Michael Crouch, Director of Business Development at TGR, said: “We’ve been impressed with Innova’s products. Their HRP conjugation kit is simple to use and at the same time provides performance that exceeds that of a range of other systems that we have tested.  We are very happy to recommend Lightning-Link to anyone who is developing assays with our CaptSure system.”

Dr Andy Lane, Executive Director at Innova Biosciences, said: "We are pleased to further develop our relationship with TGR.  Their CaptSure technology provides advantages in ELISA assay development that are directly complementary to the ethos of our conjugation technology – simplicity, high speed and enhanced sensitivity.”



Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TGR BioSciences Announces Distribution Partnership with Axxora.com
TGR BioSciences announces a distribution partnership with Axxora.com of San Diego, CA, US, a leading online global market place resource for innovative and high quality Life Science research reagents.
Tuesday, April 05, 2011
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!